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ABSTRACT
Background and the purpose of the study: Besides its hematopoietic effects, erythropoietin 
(EPO) by mobilization of iron and modulation of some inflammatory cytokines has antioxidant 
and anti-inflammatory properties. The purpose of this study was to evaluate these effects of 
erythropoietin and its impact on organ function in traumatized patients.
Methods:  Twenty-six  ICU-admitted  traumatized  patients  within  24  hrs  after  trauma  were 
randomly assigned to the EPO (received EPO, 300 units/Kg/day) and Control (not received 
EPO) groups. The inflammatory biomarkers including Tumor Necrosis Factor alpha (TNF-α), 
Interleukin 1 (IL-1), Plasminogen Activator Inhibitor 1 (PAI-1) and Nitrotyrosine were recorded 
at the admission, 3, 6 and 9 days thereafter. Acute Physiology and Chronic Health Evaluation 
(APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were also recorded.
Results: Among 12 patients (EPO group) TNF-α level at the day of 9 (P=0.046), and within EPO 
group at the days of 3 (P=0.026 ameliorate), 6 (P=0.016), and 9 (P=0.052) were significantly 
lowered. Level of IL-1 and PAI-1 decreased significantly at days of 3, 6 and 9 post intervention. 
Also there were significant differences between two groups in the SOFA score during three 
measured time intervals (the first, third and seventh days).
Conclusion: From the results of this study it seems that injection of erythrocyte stimulating 
agent is well tolerated and inhibits the inflammatory response and oxidative stress following 
trauma. 
Keywords: Anti-inflammatory, Anti-oxidative, Recombinant Human Erythropoietin, SOFA, 
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INTRODUCTION
According to WHO estimation, traumatic injuries are 
leading cause of morbidity and mortality throughout 
the  world  especially  in  underdeveloped  countries 
(1). Among different reasons and mechanisms, 
volume loss and hypovolemic shock secondary to 
hemorrhage is one of the major causes of death of 
traumatized patients (1). Although fluid therapy and 
blood transfusion play an essential role in correction 
of blood loss but, transfusion has its drawback such 
as infection transmission, acid-base disequilibrium, 
hypothermia, electrolyte disturbance, deep vein 
thrombosis,  and also decrease patient survival.
Blood  loss,  nutritional  deficiency,  and  endocrine, 
renal  and  hepatic  insufficiencies  are  some  of  the 
reasons for  anemia in  traumatized and critically 
ill patients. Erythropoietin a secreted glycoprotein 
by kidney through augmenting of hematopoietic 
remarkably  improve  anemia  and  blood  oxygen 
supply in critically ill patients (2). 
Production  and  release  of  free  radicals  following 
traumatic injury is one of the underlying mechanisms 
leading to cell injury and subsequent organ failure 
and it has been reported that excess free radicals 
overwhelmed  antioxidant  defense  of  body.  Many 
research  have  been  performed  with  antioxidant 
drugs  including  N-acetylcysteine  (3),  vitamin  C 
(4), vitamin E (5) and even iron chelators (6) for 
prevention of oxidative stress following trauma, but 
results are not convincing. In addition to the obvious 
role of EPO for treatment of anemia, several clinical 
reports  have  shown  that  it  has  also  antioxidant 
effects (7).
EPO  by  increasing  hemoxygenase-1  within  cells 
(7), degrade hem and release iron for subsequent 
utilization in hematopoisis. Metal ions especially 
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iron  by  production  of  powerful  hydroxyl  radicals 
play an important role in oxidative stress process 
and it seems that EPO mobilizes iron in blood cell 
production  cycle  and  decrease  oxidative  stress. 
Moreover, increasing numbers of circulating young 
red blood cells indirectly reduce cellular oxidative 
stress (7). This study assesses the antioxidant and 
anti-inflammatory effects of EPO on key systemic 
inflammatory response syndrome (SIRS) mediators 
in traumatized patients.
MATERIAL AND METHODS
Study design and setting 
This study was an open label randomized clinical 
trial  (Registered  under  government  ID  number 
NCT00622934), conducted at Intensive Care Unit 
of  “Sina”  teaching  hospital  (Tehran  University 
of  Medical  Sciences,  Tehran,  Iran).  Traumatized 
patients  within  24  hrs  after  trauma  referring  to 
the hospital from October 2008 to October 2009 
were enrolled in the study. In all cases, informed 
consent was obtained from patients or their closest 
relatives. The study procedure and protocol were 
approved  by  the  ethical  committee  of  Tehran 
University  of  Medical  Sciences  and  Health 
Services. Randomization was stratified by utilizing 
a computer-generated random numbers.
Study Population
All patients had been admitted to either a medical, 
surgical, or a medical/surgical ICU. Inclusion criteria 
were; staying in the ICU for 3 days, hematocrite less 
than 28%, and provision of signed informed consent. 
Exclusion criteria included age less than 18 years, 
renal failure with dialysis, new onset or uncontrolled 
seizures, acute burns, pregnancy or lactation, acute 
ischemic heart disease, acute gastrointestinal 
bleeding,  prior  treatment  with  EPO,  participation 
in  another  research  protocol,  and  expected  ICU 
discharge within 48 hrs. 
Methods
Patients were randomly assigned to two groups. In 
the EPO group (n=12), 300unit/kg of EPO (Pooyesh 
Darou-Poe  tin®,  Tehran,  Iran)  were  injected 
subcutaneously and continued every other day for 
a total of 3 doses (days of 1, 3 and 5) and followed 
up for 10 days. Blood samples were collected from 
central catheter at the day of admission and 3, 6 and 
9 days thereafter. All samples were spun for 15 min 
and plasma was stored at -800C until the time of 
analysis.
The following transfusion guideline was considered 
for the study: no RBC transfusion if the hemoglobin 
level  was  at  least  9  g/dl  or  the  hematocrite 
concentration was  at least 27%, unless there was 
a  specific  clinical  indication  (active  bleeding, 
ischemia); RBC transfusion for a hemoglobin level 
less than 9 g/dl or a hematocrite concentration less 
than 27% according to physician’s judgment. 
Patients’ clinical and preclinical characteristics 
were recorded as  follows: consciousness according 
to  the  Glasgow  Coma  Scale  (GCS),  saturation 
oxygen tension (SPO2), blood urea nitrogen (BUN), 
creatinine (Cr), serum electrolytes including sodium, 
potassium, magnesium, calcium, phosphorus, 
blood  sugar  (BS),  WBC  count,  platelet  count, 
hemoglobin, hematocrite, arterial blood gas (ABG), 
body temperature (using a rectal probe) and blood 
pressure, pulse rate, respiratory rate 4 times a day or 
according to the physician’s order. All measurements 
were performed at the admission, within the first 3 
days, and at the days of 6 and 9 after admission. 
Patients  also  underwent  Acute  Physiology  and 
Chronic  Health  Evaluation  (APACHE)  II  scores 
(8), injury severity score (ISS) (9) based on data 
obtained within the first 24 hrs after ICU admission. 
Sequential Organ Failure Assessment (SOFA) (10) 
as for organ dysfunction was assessed in the first and 
third and seventh days of admission.
All  participants  were  continuously  monitored 
for  their  hemodynamic  parameters.  Following 
biomarkers  were  considered  as  the  inflammatory 
reactants:  C-reactive  protein  (CRP),  erythrocyte 
sedimentation  rate  (ESR), Tumor  Necrosis  Factor 
alpha  (TNF-α),  interleukin  1  (IL-1),  plasminogen 
activator Plasminogen Activator Inhibitor 1 (PAI-1) 
and nitro tyrosine test (for anti-oxidant power).
Co-morbidity  factors  were  identified  from  the 
medical history including cardiac disease, chronic 
pulmonary disease, diabetes mellitus, hypertension, 
malignancy, peripheral vascular diseases, and 
embolic diseases.
Cytokine measurements
Inflammatory biomarkers concentrations in plasma 
were  measured  by  using  commercially  available 
enzyme-linked immunosorbent assay kits as follows:
TNF-α (Bender Med Systems ,Austria, Europe),IL-1 
(Bender  Med  Systems  ,Austria,  Europe),  PAI-
1 (American diagnostic,  Germany, Europe) 
and Nitrotyrosine (Hycult biotechnology b. v. , 
Netherlands, Europe) .
Statistical analyses
The  frequency  of  all  demographic  and  clinical 
characteristics  was  calculated.  Independent  two 
sample  t  test  was  used  to  compare  the  mean 
differences of the clinical and preclinical variables 
between and within groups compared to baseline. 
For non-parametric data, Mann-Whitney U test (a 
non-parametric two independent samples test) was 
used. The quantitative results are shown as mean (± 
standard deviation) or number (percent) if necessary. 
All  statistical  calculations  were  conducted  using 
SPSS ver. 14. P and values <0.05 was considered 
significant.
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RESULTS
Twelve EPO and 13 control patients with the mean 
age  of  39.33  (±23.8)  and  32.46  (±13.5)  years 
respectively  (P=0.38)  underwent  intervention. 
All  recruited  patients  were  men.  Among  26 
recruited  patients,  one  patient  was  transferred 
to  the  neurosurgery  department.  ICU  scores 
including APACHE II, and ISS scores were not 
significantly  different  between  two  groups  [The 
relevant P values (and 95% confidence interval) 
were  0.43  (-2.31_-0.04),  0.39  (-4.02_1.64)  and 
0.41 (-0.63_1.47) respectively] (Table 1). 
SOFA score was assessed in the first and third and 
seventh days, the patients who did not receive EPO 
had higher SOFA score (Table 2).
Patients’ consciousness, body temperature, blood 
pressure,  pulse  rate  (except  for  higher  pulse  rate 
within  EPO  group  at  the  6th  day,  (P=0.042)), 
respiratory  rate,  SPO2,  BUN,  Cr,  serum  sodium, 
potassium, calcium & phosphorus, blood sugar, Hb 
and  Hct  were  not  significantly  different  between 
and within groups. The Mann-Whitney test showed 
similar results, except for Hct which was higher as 
a trend within the 9th day of ICU staying (P value 
for the day of 3, 6 and 9 were 0.06, 0.08 and 0.06 
respectively).
Mann-Whitney  U  test  showed  that  TNF-α  level 
between groups at the day of 9 (P=0.046), and its 
level within EPO group at the days of 3 (P=0.026), 6 
(P=0.016), and 9 (P=0.052) were significantly lower 
(Fig 1).
IL-1 was significantly lower at the days of 3 and 
6 after treatment in EPO group [P=0.051 (95 CI: 
-0.006_3.03)  and  P=0.005  (95  CI:  0.89-4.23)] 
respectively 
Moreover, Mann-Whitney U test indicated that IL-1 
level at the day of 9 was also significantly lower in 
EPO group (P=0.030) (Fig 2).
The  relevant  independent  samples  t-test  analysis 
about PAI-1 suggest that PAI-1 levels between groups 
and within EPO group significantly decreased from 
the day of 3 (P=0.011) toward the end of treatment 
(P<0.001).  Mann-Whitney  U  test  confirmed  the 
same results (P=0.008 for the day of 3, and P<0.001 
for the rest of days) (Fig 4).
The statistical analysis (independent samples t-test) 
proposed that nitro tyrosine levels were significantly 
lower in EPO than EPO Control groups at the days 
of 6 (P=0.006, 95 CI: 2.10-10.52) and 9 (P=0.007, 
95 CI: 2.12-11.21). Applying the Mann-Whitney U 
test  indicated that nitro tyrosine level was lowered 
significantly not only at the days of 6 and 9 (P value 
were 0.046 and 0.030 respectively) between groups, 
but also within EPO group at the same days (P value 
was 0.035 for the day of 6) (Fig 3).
DISCUSSION
EPO  exerts  humeral  effects  by  means  of  its 
specific receptor (EPO-R) which does not exist in 
many tissues under normal conditions; but several 
metabolic stressors (like ischemia, hypoglycemia, 
etc) rapidly provoke up-regulation of the EPO-R 
which in turn leads to inhibition of production of 
pro-inflammatory cytokines like TNF-α, IL-1β, IL-
6, IL-8, PAF, etc (11). The cytoprotective mechanism 
of EPO is not completely understood but a probable 
explanation has been suggested (11).
Our recent investigations have revealed remarkable 
results on the role of cytokines such as IL, growth 
factors  and  oxidative  stress  mediators  in  the 
pathology or prognosis of many chronic and acute 
diseases and these issues led us to study the effect of 
Control group n=13 Epo group n=12 P Value
Age, mean (SD), year 39.33 (23.8) 32.46 (13.5) 0.667
APACHE II score, mean (SD) 19.6 19.7 0.43
ISS 13.5 13.7 0.39
SOFA 9.5 7.1 0.41
Baseline inflammatory factors
TNF-α (pg/ml) 12.32 12.21 0.824
IL1 (pg/ml) 6.43 5.34 0.301
PAI1 (ng/ml) 62.07 65.75 0.520
Nitro tyrosin (10 -9 mol) 10.7 6.15 0.299
Table 1: Baseline Characteristics.
P value Control group Epo group
0.006 9.5±0.7 7.1±0.5 Day 1 SOFA
0.002 8.8±0.8 5.8±0.5 Day3
0.001 8.9±0.9 5.3±0.5 Day7
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Figure 1: Changes in plasma concentrations of TNF-α. There were significant differences in TNF-α level 
between two groups at the day of 9 (P=0.046), and its level within EPO group at the days of 3 (P=0.026), 
6 (P=0.016), and 9 (P=0.052) compared with baseline.  
 
 
Figure 2: Changes in plasma concentrations of IL-1. There were significant differences in IL-1 between 
two groups at the days of 3 and 6 (P=0.051 and 0.005 respectively) and its level within EPO taken group 
at the day of 9 compared with baseline (P=0.030). 
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Figure 4: Changes in plasma concentrations of Plasminogen Activator Inhibitor 1 (PAI-1). There was 
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EPO on these variables (12).
In  the  present  study,  the  ICU  scores  including 
APACHE  II,  ISS  showed  insignificant 
discrepancy  between  the  study  groups;  therefore 
further comparison of clinical and para-clinical 
(inflammatory  biomarkers)  wee  made  between 
groups irrespective of the severity of trauma.
Results showed that IL-1 as an inflammatory reactant 
significantly decreased after administration of EPO 
for 3 days and this effect lasted to the 9th day after the 
treatment was started. Concerning the TNF-α, there 
was a remarkable decrease in the relevant levels after 
9 days treatment with EPO in comparison with EPO 
control  group;  and TNF-α  level  also  significantly 
decreased in the days of 3, 6 and 9 after treatment 
compared to the baseline level in the EPO group.
In agreement with reports that EPO has a variety of 
direct anti-inflammatory effects (13), results of this 
study  showed  that  EPO  significantly  diminished 
synthesis  of  anti-inflammatory  cytokines.  This 
indicates  that  the  observed  inflammatory  effects 
of EPO were not mediated by an increase in the 
principal  regulatory  cytokines,  but  were  either 
cytokine independent or mediated by a different 
cytokine(s).  Inhibition  of  apoptosis  has  been 
suggested as a fundamental mechanism of EPO-
mediated tissue protection. However, in an invitro 
model it was found that EPO rescues only a small 
number of cytokine-producing cells from apoptosis 
(data not shown).
The  cytokine  inhibitory  properties  of  EPO  likely 
represent  an  important  mechanism  by  which  its 
tissue-protective effects are mediated and evidence 
suggests that cytokine-mediated cell injury plays an 
essential role for end-organ damage (14).
 In accordance with findings of this study, it seems 
that PAI-1 was affected strongly and remarkably by 
EPO administration because its level fell significantly 
from the third day after treatment and remained 
low  during  the  study  period.  PAI-1  is  the  major 
physiological inhibitor of tissue type plasminogen 
activator. PAI-1 is an inhibitor of fibrinolysis and 
increase in its levels are considered to contribute to 
the pro-coagulant state associated with thrombotic 
diseases.
In  the  past  study  it  was  found  that  PAI-1  level 
decreased in both intensive insulin therapy and /or 
combined with metformin (15). Consistent with these 
results it has been reported that glucose control and 
insulin treatment improved fibrinolysis by reducing 
PAI-1  concentration/  activity  (16)  and  impaired 
fibrinolysis during sepsis has been associated with 
widespread activation of coagulation  through the   
release of inflammatory cytokines (17).
Nitrotyrosine  was  significantly  lower  in  the  EPO 
treated patients at the days of 3, 6 and 9 after treatment 
compared with control patients; in addition its level 
decreased significantly at the days of 3 and 6 in the 
EPO group in comparison to their baseline values.
EPO may exert its anti oxidative effects directly by 
exploiting intracellular anti oxidative mechanisms. 
Increase in the red blood cells by EPO may also 
indirectly  reduce  cellular  oxidative  stress,  as  red 
blood cells are loaded with a substantial amount of 
antioxidative enzymes. 
A  comparison  of  SOFA  scores  on  the  first,  third 
and seventh day showed that EPO group had lower 
SOFA score which at least indicate that EPO has 
anti-inflammatory activity. 
 SOFA score was selected as a quantitative tool to 
judge this matter to some extent because it represents 
the dynamics of illness including the effectiveness 
of therapy.
Among critically ill patients, erythropoietin uses 
appears to be associated with increased thrombotic 
events. This is consistent with the results of recent 
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trials involving non- critically ill patients with either 
cancer  or  chronic  renal  failure.  In  these  studies, 
when  erythropoietin,  was  used  to  achieve  higher 
target hemoglobin concentrations (i.e., > 120 g/l), 
the risk of thrombotic complications and death were 
increased (18, 19). Importantly, patients with past 
thromboembolic complications had to be strictly 
excluded, and therefore patients who are prone to 
bed should not be included in a chronic treatment 
study. However findings of this study did not show 
any thromboembolic complications because Platelet 
counts and other related factors had been carefully 
and continuously monitored at all times of EPO 
treatment and even in weeks thereafter. Other side-
effects such as hypertension and allergic reactions 
have been reported (20).
CONCLUSION
Administration of recombinant human erythro-
poietin  for  ICU-admitted  traumatized  patients 
seems  beneficial  as  it  may  helps  to  restrain  the 
inflammation and oxidative injuries, which in turn 
may lead to improved prognosis during and after 
ICU admission.
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